The US Justice Department charged several people with insider trading and market manipulation in a case that centers on California biotech Olema Oncology and its lead candidate for breast cancer. Brothers Muhammad Saad Shoukat and …
Uzbek Users Under Attack by Android SMS Stealers
Telegram users in Uzbekistan are being targeted with Android SMS stealer malware, and what’s worse, the attackers are improving their methods.
Toward Inclusive Design Heuristics for Digital Health Interventions for the Aging Population: Scoping Review
Background: Digital health interventions (DHI) deliver health-related services in a digital manner. Meant for older adults, they must be tailored to address their needs. This may be by applying inclusive design principles. Inclusive design is an approach that aims to accommodate the needs of a broad spectrum of users, taking into account health-related factors, socioeconomic […]
Windward gets bispecific from Qyuns in its second China deal of the year
Swiss biotech Windward Bio is picking up a second drug candidate from a China biotech this year, seeking to bring multiple medicines to market for respiratory and dermatology conditions. Windward is paying up to …
Shionogi will pay $2.5B to acquire one of the only approved ALS drugs
The Japanese drugmaker Shionogi announced Monday that it will be taking ownership of one of the only approved ALS drugs in a multibillion-dollar deal, with implications for its broader ambitions in rare disease. The company …
Andexxa reaches the end of the line in the US
AstraZeneca will voluntarily take its anticoagulant reversal agent Andexxa off the market in the US amid reports of serious clotting side effects.
Ipsen gains access to ADC from Shanghai biotech Simcere Zaiming
Ipsen extended its 18-month dealmaking streak, lining up an antibody-drug conjugate from Shanghai-based Simcere Zaiming. Paris-based Ipsen will pay $45 million upfront for access to an antibody-drug conjugate outside of Greater China, according to a …
Ipsen licenses Simcere ADC in $1bn-plus deal
Deal-hungry Ipsen is at it again, pledging around $1bn for rights to an antibody-drug conjugate (ADC) for cancer developed by China’s Simcere.
Boehringer taps Rectify to create pills for chronic kidney disease
Boehringer Ingelheim will work with a Boston startup to develop oral medicines for chronic kidney diseases in a partnership worth up to $448 million in biobucks. The move boosts the profile of the nimble Rectify …
AZ’s ATR inhibitor ceralasertib flunks lung cancer test
AstraZeneca has had a setback in its oncology pipeline, as AKT inhibitor ceralasertib fails to improve survival in a phase 3 lung cancer trial.